Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in J Neurochem

Retrieve available abstracts of 108 articles:
HTML format



Single Articles


    June 2024
  1. ISEI MO, Girardi PA, Rodwell-Bullock J, Nehrke K, et al
    Site-specific phosphorylation of tau impacts mitochondrial function and response to stressors.
    J Neurochem. 2024;168:1019-1029.
    PubMed     Abstract available


    May 2024
  2. CHEN Y, Zeng X, Diaz JL, Sehrawat A, et al
    Effect of blood collection tube containing protease inhibitors on the pre-analytical stability of Alzheimer's disease plasma biomarkers.
    J Neurochem. 2024 May 30. doi: 10.1111/jnc.16130.
    PubMed     Abstract available


    April 2024

  3. The following article for this Special Issue was previously published and can be found in its respective issue online: "Detection of early Alzheimer's disease-like molecular alterations in a mouse model expressing human ApoE4".
    J Neurochem. 2024;168:e2.
    PubMed     Abstract available


  4. KWAN KH, Soreq H
    EDITOR SPOTLIGHT: Interview with Cholinergic Mechanisms Special Issue Guest Editor Hermona Soreq.
    J Neurochem. 2024;168:331-333.
    PubMed     Abstract available


    March 2024
  5. NETZAHUALCOYOTZI C, Santillan-Cigales JJ, Adalid-Peralta LV, Velasco I, et al
    Infiltration of immune cells to the brain and its relation to the pathogenesis of Alzheimer's and Parkinson's diseases.
    J Neurochem. 2024 Mar 29. doi: 10.1111/jnc.16106.
    PubMed     Abstract available


  6. ZHANG JF, Fang ZT, Zhao JN, Liu GP, et al
    Acetylated tau exacerbates apoptosis by disturbing mitochondrial dynamics in HEK293 cells.
    J Neurochem. 2024;168:288-302.
    PubMed     Abstract available


    February 2024
  7. PEREIRA JD, Teixeira LCR, Mamede I, Alves MT, et al
    miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach.
    J Neurochem. 2024 Feb 23. doi: 10.1111/jnc.16060.
    PubMed     Abstract available


  8. HANRIEDER J
    Lipid imaging of Alzheimer's disease pathology.
    J Neurochem. 2024 Feb 19. doi: 10.1111/jnc.16079.
    PubMed     Abstract available


  9. FERNANDES T, Melo T, Conde T, Neves B, et al
    Mapping the lipidome in mitochondria-associated membranes (MAMs) in an in vitro model of Alzheimer's disease.
    J Neurochem. 2024 Feb 7. doi: 10.1111/jnc.16072.
    PubMed     Abstract available


  10. LIANG Y, Deng MG, Jian Q, Liu M, et al
    Maternal history of Alzheimer's disease predisposes to altered serum cholesterol levels in adult offspring.
    J Neurochem. 2024 Feb 5. doi: 10.1111/jnc.16056.
    PubMed     Abstract available


  11. SU M, Xuan E, Sun X, Pan G, et al
    Synaptic adhesion molecule protocadherin-gammaC5 mediates beta-amyloid-induced neuronal hyperactivity and cognitive deficits in Alzheimer's disease.
    J Neurochem. 2024 Feb 3. doi: 10.1111/jnc.16066.
    PubMed     Abstract available


  12. FRANCIS JS, Nguyen Q, Markov V, Leone P, et al
    Over-expression of N-acetylaspartate synthase exacerbates pathological energetic deficit and accelerates cognitive decline in the 5xFAD mouse.
    J Neurochem. 2024;168:69-82.
    PubMed     Abstract available


    December 2023
  13. SALCEDO C, Pozo Garcia V, Garcia-Adan B, Ameen AO, et al
    Increased glucose metabolism and impaired glutamate transport in human astrocytes are potential early triggers of abnormal extracellular glutamate accumulation in hiPSC-derived models of Alzheimer's disease.
    J Neurochem. 2023 Dec 8. doi: 10.1111/jnc.16014.
    PubMed     Abstract available


  14. GAO PY, Ou YN, Huang YM, Wang ZB, et al
    Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study.
    J Neurochem. 2023 Dec 6. doi: 10.1111/jnc.16025.
    PubMed     Abstract available


  15. HUANG SY, Zhang YR, Yang L, Li YZ, et al
    Circulating metabolites and risk of incident dementia: A prospective cohort study.
    J Neurochem. 2023;167:668-679.
    PubMed     Abstract available


    November 2023
  16. QIN H, Zhou L, Haque FT, Martin-Jimenez C, et al
    Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease.
    J Neurochem. 2023 Nov 6. doi: 10.1111/jnc.16002.
    PubMed     Abstract available


  17. HAMILTON K, Morrow K, Markantoni E, Harvey J, et al
    Leptin prevents aberrant targeting of tau to hippocampal synapses via PI 3 kinase driven inhibition of GSK3beta.
    J Neurochem. 2023;167:520-537.
    PubMed     Abstract available


    October 2023
  18. FURMAN S, Green K, Lane TE
    COVID-19 and the impact on Alzheimer's disease pathology.
    J Neurochem. 2023 Oct 18. doi: 10.1111/jnc.15985.
    PubMed     Abstract available


  19. TURNER AJ
    Book Review: Alzheimer's Disease Research: What has guided research so far and why it is high time for a paradigm shift (Christian Behl. Springer Nature, Switzerland, 2023) 661 pp.
    J Neurochem. 2023 Oct 14. doi: 10.1111/jnc.15989.
    PubMed     Abstract available


  20. SAMUELS JD, Lukens JR, Price RJ
    Emerging roles for ITAM and ITIM receptor signaling in microglial biology and Alzheimer's disease-related amyloidosis.
    J Neurochem. 2023 Oct 11. doi: 10.1111/jnc.15981.
    PubMed     Abstract available


    September 2023
  21. WANG R, Lu KP, Zhou XZ
    Function and regulation of cis P-tau in the pathogenesis and treatment of conventional and nonconventional tauopathies.
    J Neurochem. 2023;166:904-914.
    PubMed     Abstract available


  22. SAEZ-VALERO J, Perez-Gonzalez R
    BACE2 beyond beta-processing of APP, its neuroprotective role in cerebrovascular endothelium.
    J Neurochem. 2023;166:887-890.
    PubMed     Abstract available


  23. CHENG JY, Deng YT, Yu JT
    The causal role of circulating amino acids on neurodegenerative disorders: A two-sample Mendelian randomization study.
    J Neurochem. 2023;166:972-981.
    PubMed     Abstract available


    August 2023
  24. LAU SF, Fu AKY, Ip NY
    Receptor-ligand interaction controls microglial chemotaxis and amelioration of Alzheimer's disease pathology.
    J Neurochem. 2023 Aug 21. doi: 10.1111/jnc.15933.
    PubMed     Abstract available


  25. CUENCA-BERMEJO L, Prinetti A, Kublickiene K, Raparelli V, et al
    Fundamental neurochemistry review: Old brain stories - Influence of age and sex on the neurodegeneration-associated lipid changes.
    J Neurochem. 2023;166:427-452.
    PubMed     Abstract available


    July 2023
  26. WARTH PEREZ ARIAS CC, Silbern I, Caldi Gomes L, Wartmann H, et al
    Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson's disease.
    J Neurochem. 2023 Jul 28. doi: 10.1111/jnc.15924.
    PubMed     Abstract available


  27. RAI A, Ojiakor OA, Rylett RJ
    Detection of early Alzheimer's disease-like molecular alterations in a mouse model expressing human ApoE4.
    J Neurochem. 2023 Jul 6. doi: 10.1111/jnc.15904.
    PubMed     Abstract available


  28. MOREIRA GG, Gomes CM
    Tau liquid-liquid phase separation is modulated by the Ca(2+) -switched chaperone activity of the S100B protein.
    J Neurochem. 2023;166:76-86.
    PubMed     Abstract available


  29. MATAFORA V, Gorb A, Yang F, Noble W, et al
    Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Abeta.
    J Neurochem. 2023;166:346-366.
    PubMed     Abstract available


  30. SECKER C, Motzny AY, Kostova S, Buntru A, et al
    The polyphenol EGCG directly targets intracellular amyloid-beta aggregates and promotes their lysosomal degradation.
    J Neurochem. 2023;166:294-317.
    PubMed     Abstract available


  31. SANTIAGO TC, Parra L, Nani JV, Fidalgo TM, et al
    Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders.
    J Neurochem. 2023;166:138-155.
    PubMed     Abstract available


    June 2023
  32. ANDERSON T, Sharma S, Kelberman MA, Ware C, et al
    Obesity during preclinical Alzheimer's disease development exacerbates brain metabolic decline.
    J Neurochem. 2023 Jun 30. doi: 10.1111/jnc.15900.
    PubMed     Abstract available


  33. MAKSOUR S, Ooi L
    Innovations advancing our understanding of microglia in Alzheimer's disease: From in vitro to in vivo models.
    J Neurochem. 2023 Jun 15. doi: 10.1111/jnc.15885.
    PubMed     Abstract available


  34. ZHAO Y, Zhou H, Zhao Y, Liang Z, et al
    BACE1 SUMOylation deregulates phosphorylation and ubiquitination in Alzheimer's disease pathology.
    J Neurochem. 2023 Jun 7. doi: 10.1111/jnc.15870.
    PubMed     Abstract available


  35. HE RB, Li L, Liu LZ, Ma YJ, et al
    Ceftriaxone improves impairments in synaptic plasticity and cognitive behavior in APP/PS1 mouse model of Alzheimer's disease by inhibiting extrasynaptic NMDAR-STEP(61) signaling.
    J Neurochem. 2023 Jun 7. doi: 10.1111/jnc.15874.
    PubMed     Abstract available


  36. BARINGER SL, Simpson IA, Connor JR
    Brain iron acquisition: An overview of homeostatic regulation and disease dysregulation.
    J Neurochem. 2023;165:625-642.
    PubMed     Abstract available


  37. GROVER S, Pham T, Jones A, Sinobas-Pereira C, et al
    A new class of monoclonal Abeta antibodies selectively targets and triggers deposition of Abeta protofibrils.
    J Neurochem. 2023;165:860-873.
    PubMed     Abstract available


  38. DOHERTY G, Holiday A, Malekizadeh Y, Manolescu C, et al
    Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
    J Neurochem. 2023;165:809-826.
    PubMed     Abstract available


    May 2023
  39. FLEEMAN RM, Kuhn MK, Chan DC, Proctor EA, et al
    Apolipoprotein E epsilon4 modulates astrocyte neuronal support functions in the presence of amyloid-beta.
    J Neurochem. 2023;165:536-549.
    PubMed     Abstract available


    April 2023
  40. MOK KK, Yeung SH, Cheng GW, Ma IW, et al
    Apolipoprotein E epsilon4 disrupts oligodendrocyte differentiation by interfering with astrocyte-derived lipid transport.
    J Neurochem. 2023;165:55-75.
    PubMed     Abstract available


    March 2023
  41. CARNA M, Novotny JS, Dragisic N, Slavik H, et al
    Missorting of Plasma miRNAs in Aging and Alzheimer's Disease.
    J Neurochem. 2023 Mar 9. doi: 10.1111/jnc.15801.
    PubMed     Abstract available


  42. WENZEL TJ, Le J, He J, Alcorn J, et al
    Fundamental Neurochemistry Review: Incorporating a greater diversity of cell types, including microglia, in brain organoid cultures improves clinical translation.
    J Neurochem. 2023;164:560-582.
    PubMed     Abstract available


  43. LOEFFLER DA
    Experimental approaches for altering the expression of Abeta-degrading enzymes.
    J Neurochem. 2023;164:725-763.
    PubMed     Abstract available


  44. SUN Y, Islam S, Gao Y, Nakamura T, et al
    Apolipoprotein E4 inhibits gamma-secretase activity via binding to the gamma-secretase complex.
    J Neurochem. 2023;164:858-874.
    PubMed     Abstract available


  45. TORTUYAUX R, Avila-Gutierrez K, Oudart M, Mazare N, et al
    Physiopathological changes of ferritin mRNA density and distribution in hippocampal astrocytes in the mouse brain.
    J Neurochem. 2023;164:847-857.
    PubMed     Abstract available


    February 2023
  46. JHA D, Bakker ENTP, Kumar R
    Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's Disease.
    J Neurochem. 2023 Feb 18. doi: 10.1111/jnc.15788.
    PubMed     Abstract available


  47. LI S
    The beta-adrenergic hypothesis of synaptic and microglial impairment in Alzheimer's disease.
    J Neurochem. 2023 Feb 17. doi: 10.1111/jnc.15782.
    PubMed     Abstract available


  48. HOENIG MC, Drzezga A
    Clear-headed into old age: Resilience and resistance against brain aging-A PET imaging perspective.
    J Neurochem. 2023;164:325-345.
    PubMed     Abstract available


    January 2023
  49. KURZ C, Stockl L, Schrurs I, Suridjan I, et al
    Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
    J Neurochem. 2023 Jan 10. doi: 10.1111/jnc.15757.
    PubMed     Abstract available


  50. XIONG W, Cai J, Sun B, Lin H, et al
    The Association between Genetic Variations and Morphology-based Brain Networks Changes in Alzheimer's Disease.
    J Neurochem. 2023 Jan 10. doi: 10.1111/jnc.15761.
    PubMed     Abstract available


  51. RABL M, Clark C, Dayon L, Bowman GL, et al
    Blood plasma protein profiles of neuropsychiatric symptoms and related cognitive decline in older people.
    J Neurochem. 2023;164:242-254.
    PubMed     Abstract available


    December 2022
  52. MENG D, Yang M, Hu L, Liu T, et al
    Rifaximin protects against circadian rhythm disruption-induced cognitive impairment through preventing gut barrier damage and neuroinflammation.
    J Neurochem. 2022;163:406-418.
    PubMed     Abstract available


  53. YAMAMOTO N, Tokumon T, Obuchi A, Kono M, et al
    Poly(I:C) promotes neurotoxic amyloid beta accumulation through reduced degradation by decreasing neprilysin protein levels in astrocytes.
    J Neurochem. 2022;163:517-530.
    PubMed     Abstract available


    November 2022
  54. GARCIA-SEGURA ME, Durainayagam BR, Liggi S, Graca G, et al
    Pathway-based integration of multi-omics data reveals lipidomics alterations validated in an Alzheimer s Disease mouse model and risk loci carriers.
    J Neurochem. 2022 Nov 3. doi: 10.1111/jnc.15719.
    PubMed     Abstract available


  55. SEPULVEDA J, Luo N, Nelson M, Ng CAS, et al
    Independent APOE4 knock-in mouse models display reduced brain APOE protein, altered neuroinflammation, and simplification of dendritic spines.
    J Neurochem. 2022;163:247-259.
    PubMed     Abstract available


    October 2022
  56. MUKHERJEE S, Dubois C, Perez K, Varghese S, et al
    Quantitative proteomics of tau and Abeta in detergent fractions from Alzheimer's disease brains.
    J Neurochem. 2022 Oct 21. doi: 10.1111/jnc.15713.
    PubMed     Abstract available


  57. DUARTE JMN
    Serine racemase modulation for improving brain insulin resistance: An Editorial Highlight for "Deletion of serine racemase reverses neuronal insulin signaling inhibition by amyloid-beta oligomers": An Editorial Highlight for "Deletion of serine racema
    J Neurochem. 2022;163:6-7.
    PubMed     Abstract available


  58. ZHOU J, Zhang Z, Yang Y, Liao F, et al
    Deletion of serine racemase reverses neuronal insulin signaling inhibition by amyloid-beta oligomers.
    J Neurochem. 2022;163:8-25.
    PubMed     Abstract available


    September 2022
  59. VAZ M, Martins TS, Henriques AG
    Extracellular vesicles in the study of Alzheimer's and Parkinson's diseases: methodologies applied from cells to biofluids.
    J Neurochem. 2022 Sep 26. doi: 10.1111/jnc.15697.
    PubMed     Abstract available


  60. MICHNO W, Koutarapu S, Camacho R, Toomey C, et al
    Chemical traits of cerebral amyloid angiopathy in familial British-, Danish- and non-Alzheimer's dementias.
    J Neurochem. 2022 Sep 14. doi: 10.1111/jnc.15694.
    PubMed     Abstract available


    August 2022
  61. GALGANI A, Vergallo A, Campese N, Lombardo F, et al
    Biological determinants of blood-based cytokines in the Alzheimer's Disease clinical continuum.
    J Neurochem. 2022 Aug 11. doi: 10.1111/jnc.15686.
    PubMed     Abstract available


  62. DEVINA T, Wong YH, Hsiao CW, Li YJ, et al
    Endoplasmic reticulum stress induces Alzheimer's disease-like phenotypes in the neuron derived from the induced pluripotent stem cell with D678H mutation on amyloid precursor protein.
    J Neurochem. 2022 Aug 9. doi: 10.1111/jnc.15687.
    PubMed     Abstract available


  63. DI RISOLA D, Ricci D, Marrocco I, Giamogante F, et al
    ERp57 chaperon protein protects neuronal cells from Abeta-induced toxicity.
    J Neurochem. 2022;162:322-336.
    PubMed     Abstract available


    July 2022
  64. PEDRINI S, Doecke JD, Hone E, Wang P, et al
    Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume.
    J Neurochem. 2022 Jul 30. doi: 10.1111/jnc.15681.
    PubMed     Abstract available


    May 2022
  65. QIN YR, Ma CQ, Jiang JH, Wang DP, et al
    Artesunate restores mitochondrial fusion-fission dynamics and alleviates neuronal injury in Alzheimer's disease models.
    J Neurochem. 2022 May 21. doi: 10.1111/jnc.15620.
    PubMed     Abstract available


  66. YU ZY, Yi X, Wang YR, Zeng GH, et al
    Inhibiting alpha1-adrenergic receptor signaling pathway ameliorates AD-type pathologies and behavioral deficits in APPswe/PS1 mouse model.
    J Neurochem. 2022;161:293-307.
    PubMed     Abstract available


  67. LOURENCO MV, Hausmann L
    Editorial: Honouring John Hardy - A true pioneer in research.
    J Neurochem. 2022;161:316-319.
    PubMed     Abstract available


    April 2022
  68. TURATI J, Rudi J, Beauquis J, Carniglia L, et al
    A metabotropic glutamate receptor 3 (mGlu3R) isoform playing neurodegenerative roles in astrocytes is prematurely up-regulated in an Alzheimer's model.
    J Neurochem. 2022 Apr 11. doi: 10.1111/jnc.15610.
    PubMed     Abstract available


  69. ZIFF OJ, Ashton NJ, Mehta PR, Brown R, et al
    Amyloid processing in COVID-19-associated neurological syndromes.
    J Neurochem. 2022;161:146-157.
    PubMed     Abstract available


    March 2022
  70. KLAFKI HW, Wirths O, Mollenhauer B, Liepold T, et al
    Detection and quantification of Abeta-3-40 (APP669-711) in cerebrospinal fluid.
    J Neurochem. 2022;160:578-589.
    PubMed     Abstract available


    February 2022
  71. MICHNO W, Wehrli PM, Koutarapu S, Marsching C, et al
    Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging.
    J Neurochem. 2022;160:482-498.
    PubMed     Abstract available


    January 2022
  72. LOPES CR, Amaral IM, Pereira MF, Lopes JP, et al
    Impact of blunting astrocyte activity on hippocampal synaptic plasticity in a mouse model of early Alzheimer's disease based on amyloid-beta peptide exposure.
    J Neurochem. 2022 Jan 19. doi: 10.1111/jnc.15575.
    PubMed     Abstract available


    December 2021
  73. KASICA NP, Zhou X, Yang Q, Wang X, et al
    Antagonists targeting eEF2 kinase rescue multiple aspects of pathophysiology in Alzheimer's disease model mice.
    J Neurochem. 2021 Dec 21. doi: 10.1111/jnc.15562.
    PubMed     Abstract available


  74. KUMAR A, Fontana IC, Nordberg A
    Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease.
    J Neurochem. 2021 Dec 20. doi: 10.1111/jnc.15565.
    PubMed     Abstract available


  75. FARUK MO, Tsuboi D, Yamahashi Y, Funahashi Y, et al
    Muscarinic signaling regulates voltage-gated potassium channel KCNQ2 phosphorylation in the nucleus accumbens via protein kinase C for aversive learning.
    J Neurochem. 2021 Dec 8. doi: 10.1111/jnc.15555.
    PubMed     Abstract available


    November 2021
  76. MA T
    Roles of eukaryotic elongation factor 2 kinase (eEF2K) in neuronal plasticity, cognition, and Alzheimer's disease.
    J Neurochem. 2021 Nov 19. doi: 10.1111/jnc.15541.
    PubMed     Abstract available


  77. MATUSZYK MM, Garwood CJ, Ferraiuolo L, Simpson JE, et al
    Biological and Methodological Complexities of Beta-Amyloid Peptide; Implications for Alzheimer's Disease Research.
    J Neurochem. 2021 Nov 12. doi: 10.1111/jnc.15538.
    PubMed     Abstract available


  78. ZULIANI G, Trentini A, Brombo G, Rosta V, et al
    Serum beta-secretase 1 (BACE1) activity increases in patients with mild cognitive impairment.
    J Neurochem. 2021;159:629-637.
    PubMed     Abstract available


    October 2021
  79. HANRIEDER J
    Preface: Mass spectrometry in Alzheimer disease: This is the Preface for the special issue "Mass Spectrometry in Alzheimer Disease".
    J Neurochem. 2021;159:207-210.
    PubMed     Abstract available


  80. GKANATSIOU E, Nilsson J, Toomey CE, Vrillon A, et al
    Amyloid pathology and synaptic loss in pathological aging.
    J Neurochem. 2021;159:258-272.
    PubMed     Abstract available


    September 2021
  81. JAKARIA M, Belaidi AA, Bush AI, Ayton S, et al
    Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease.
    J Neurochem. 2021 Sep 23. doi: 10.1111/jnc.15519.
    PubMed     Abstract available


  82. GEULA C, Dunlop SR, Ayala I, Kawles AS, et al
    Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.
    J Neurochem. 2021;158:1394-1411.
    PubMed     Abstract available


    July 2021
  83. MICHNO W, Blennow K, Zetterberg H, Brinkmalm G, et al
    Refining the amyloid beta peptide and oligomer fingerprint ambiguities in Alzheimer's disease: mass spectrometric molecular characterization in brain, CSF, blood and plasma.
    J Neurochem. 2021 Jul 10. doi: 10.1111/jnc.15466.
    PubMed     Abstract available


  84. KORECKA M, Shaw LM
    Mass spectrometry-based methods for robust measurement of Alzheimer's Disease biomarkers in biological fluids.
    J Neurochem. 2021 Jul 10. doi: 10.1111/jnc.15465.
    PubMed     Abstract available



  85. Retraction: Clinical trials in Alzheimer's disease': immunotherapy approaches.
    J Neurochem. 2021 Jul 6. doi: 10.1111/jnc.15435.
    PubMed     Abstract available


  86. WANG XM, Zeng P, Fang YY, Zhang T, et al
    Progranulin in neurodegenerative dementia.
    J Neurochem. 2021;158:119-137.
    PubMed     Abstract available


  87. XU L, Tian S, Peng X, Hua Y, et al
    Clusterin inhibits Abeta42 aggregation through a "strawberry model" as detected by FRET-FCS.
    J Neurochem. 2021;158:444-454.
    PubMed     Abstract available


    June 2021
  88. CORTES-GOMEZ MA, Llorens-Alvarez E, Alom J, Del Ser T, et al
    Tau phosphorylation by glycogen synthase kinase 3beta modulates enzyme acetylcholinesterase expression.
    J Neurochem. 2021;157:2091-2105.
    PubMed     Abstract available


    May 2021
  89. LI KY, Xiang XJ, Song L, Chen J, et al
    Mitochondrial TXN2 attenuates amyloidogenesis via selective inhibition of BACE1 expression.
    J Neurochem. 2021;157:1351-1365.
    PubMed     Abstract available


    April 2021
  90. LEE-LIU D, Gonzalez-Billault C
    Neuron-intrinsic origin of hyperexcitability during early pathogenesis of Alzheimer's disease: An Editorial Highlight for "Hippocampal hyperactivity in a rat model of Alzheimer's disease" on https://doi.org/10.1111/jnc.15323.
    J Neurochem. 2021 Apr 28. doi: 10.1111/jnc.15248.
    PubMed     Abstract available


  91. SUN L, Bhawal R, Xu H, Chen H, et al
    The human brain acetylome reveals that decreased acetylation of mitochondrial proteins associates with Alzheimer's disease.
    J Neurochem. 2021 Apr 27. doi: 10.1111/jnc.15377.
    PubMed     Abstract available


  92. VAN DER VELPEN V, Rosenberg N, Maillard V, Teav T, et al
    Sex-specific alterations in NAD+ metabolism in triple transgenic Alzheimer's disease mouse brain assessed by quantitative targeted liquid chromatography - mass spectrometry.
    J Neurochem. 2021 Apr 8. doi: 10.1111/jnc.15362.
    PubMed     Abstract available


    March 2021
  93. BUTLER CA, Thornton P, Brown GC
    CD33M inhibits microglial phagocytosis, migration and proliferation, but the Alzheimer's disease-protective variant CD33m stimulates phagocytosis and proliferation, and inhibits adhesion.
    J Neurochem. 2021 Mar 15. doi: 10.1111/jnc.15349.
    PubMed     Abstract available


  94. CHEN H, Cross AC, Thakkar A, Xu H, et al
    Selective linkage of mitochondrial enzymes to intracellular calcium stores differs between human-induced pluripotent stem cells, neural stem cells, and neurons.
    J Neurochem. 2021;156:867-879.
    PubMed     Abstract available


    February 2021
  95. SOSULINA L, Mittag M, Geis HR, Hoffmann K, et al
    Hippocampal hyperactivity in a rat model of Alzheimer's disease.
    J Neurochem. 2021 Feb 14. doi: 10.1111/jnc.15323.
    PubMed     Abstract available


  96. ARBER C, Alatza A, Leckey CA, Paterson RW, et al
    Mass spectrometry analysis of tau and amyloid-beta in iPSC-derived models of Alzheimer's disease and dementia.
    J Neurochem. 2021 Feb 4. doi: 10.1111/jnc.15315.
    PubMed     Abstract available


    January 2021
  97. HUANG SJ, Ma YH, Bi YL, Shen XN, et al
    Metabolically healthy obesity and lipids may be protective factors for pathological changes of Alzheimer's disease in cognitively normal adults.
    J Neurochem. 2021 Jan 18. doi: 10.1111/jnc.15306.
    PubMed     Abstract available


  98. GRUNDER G, Cumming P
    Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Abeta production and related pathology in a mouse model of Alzheimer's
    J Neurochem. 2021 Jan 18. doi: 10.1111/jnc.15269.
    PubMed     Abstract available


  99. HARK TJ, Savas JN
    Using stable isotope labeling to advance our understanding of Alzheimer's disease etiology and pathology.
    J Neurochem. 2021 Jan 12. doi: 10.1111/jnc.15298.
    PubMed     Abstract available


    December 2020
  100. HIGHET B, Anekal PV, Ryan B, Murray H, et al
    fISHing with immunohistochemistry for housekeeping gene changes in Alzheimer's disease using an automated quantitative analysis workflow.
    J Neurochem. 2020 Dec 25. doi: 10.1111/jnc.15283.
    PubMed     Abstract available


  101. STOLERO N, Frenkel D
    The Dialog between Neurons and Microglia in Alzheimer's Disease: The Neurotransmitters View.
    J Neurochem. 2020 Dec 12. doi: 10.1111/jnc.15262.
    PubMed     Abstract available


  102. YUEDE CM, Wallace CE, Davis TA, Gardiner WD, et al
    Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Abeta production and related pathology in a mouse model of Alzheimer's disease.
    J Neurochem. 2020 Dec 5. doi: 10.1111/jnc.15260.
    PubMed     Abstract available


  103. GULYAEVA NV
    Hippocampal hyperglutamatergic signaling matters: Early targeting glutamate neurotransmission as a preventive strategy in Alzheimer's disease: An Editorial Highlight for "Riluzole attenuates glutamatergic tone and cognitive decline in AbetaPP/PS1 mice
    J Neurochem. 2020 Dec 4. doi: 10.1111/jnc.15238.
    PubMed     Abstract available


  104. LI W, Wu M, Zhang Y, Wei X, et al
    Intermittent fasting promotes adult hippocampal neuronal differentiation by activating GSK-3beta in 3xTg-AD mice.
    J Neurochem. 2020;155:697-713.
    PubMed     Abstract available


    November 2020
  105. LI L, Miao M, Chen J, Liu Z, et al
    Role of Tet2 in modulating neuronal morphology and cognition in a mouse model of Alzheimer's disease.
    J Neurochem. 2020 Nov 9. doi: 10.1111/jnc.15234.
    PubMed     Abstract available


  106. VINKLAROVA L, Schmidt M, Benek O, Kuca K, et al
    Friend or enemy? Review of 17beta-HSD10 and its role in human health or disease.
    J Neurochem. 2020;155:231-249.
    PubMed     Abstract available


    October 2020
  107. LIMEGROVER CS, LeVine H 3rd, Izzo NJ, Yurko R, et al
    Alzheimer's Protection Effect of A673T Mutation May Be Driven by Lower Abeta Oligomer Binding Affinity.
    J Neurochem. 2020 Oct 6. doi: 10.1111/jnc.15212.
    PubMed     Abstract available


    September 2020
  108. GAUNITZ S, Tjernberg LO, Schedin-Weiss S
    The N-glycan profile in cortex and hippocampus is altered in Alzheimer s disease.
    J Neurochem. 2020 Sep 28. doi: 10.1111/jnc.15202.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.